TNFRSF12A and multiple sclerosis: Consistently, anti-TWEAK-neutralizing monoclonal antibodies were shown to reduce inflammatory cell infiltration in mice models of multiple sclerosis and rheumatoid arthritis, whereas Fn14-null mice demonstrated a deficient inflammatory response upon tissue injury [41,42,43,44,45].